December 15th, 2015

Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug

[Reuters] – Slowing sales of Biogen Inc’s key oral multiple sclerosis (MS) drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer’s drug sent the company’s stock down as . . . → Read More: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Similar Articles: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.